Delayed Bone Age Might Accelerate the Response to Human Growth Hormone Treatment in Small for Gestational Age Children with Short Stature

Table 3

Initial clinical and laboratory characteristics when classified according to whether patients had bone age (BA) delay of more or less than 2 years.

	<2 yr BA delayed group (N = 9)	>2 yr BA delayed group (N = 18)
M : F	0 : 9	10 : 8	value
Gestational age (months)	38.0 ± 2.2	37.6 ± 3.0	0.726
Birth weight (g)	2234.4 ± 374.9	2241.7 ± 489.4	0.969
Age (years)	8.1 ± 1.6	6.7 ± 1.9	0.061
BMI (kg/m^2, Z score)	−0.46 ± 0.86	−0.53 ± 0.97	0.844
Height SDS	−2.67 ± 0.58	−2.45 ± 0.34	0.210
BA (years)	7.6 ± 2.1	3.6 ± 1.9	0.001
CA-BA (years)	0.5 ± 0.9	3.0 ± 0.9	0.001
BA/CA	0.93 ± 0.12	0.51 ± 0.14	0.001
IGF-1 SDS	−1.07 ± 0.77	−1 ± 0.87	0.842
rhGH (IU/kg/day)	0.17 ± 0.04	0.14 ± 0.02	0.074

N, number; M : F, male: female (number); BA, bone age; CA-BA, differences between bone age and chronological age; BA/CA, bone age to chronological age ratio; rhGH, recombinant human growth hormone; GHD, growth hormone deficiency.